Nicholas Pulliam, PhD, is the Scientific Lead in Translational Sciences at Eli Lilly and Company, where they leverage their expertise in cancer research and molecular biology. They previously served as a PhD Candidate at Indiana University Bloomington, focusing on the efficacy of combination epigenetic and PARP inhibitor therapies in cancers. Nicholas also held roles in Global Scientific Communication at Eli Lilly, supporting numerous oncology publications and building strong stakeholder relationships. Additionally, they are currently an Adjunct Professor in Biology at Ivy Tech Community College and serve on the Advisory Board for Valparaiso University.
This person is not in any teams
This person is not in any offices